GlobeNewswire

ObsEva Annual General Meeting 2021

Share

Geneva, Switzerland and Boston, MA – April 22, 2021– ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today published the invitation to its 2021 Annual General Meeting of Shareholders to be held on May 28, 2021 at 16:30 CEST at the company’s offices in Geneva, Chemin des Aulx 12, 3rd floor, 1228 Plan-les-Ouates, Switzerland.

The agenda of the meeting will be as follows:

1Approval of the Annual Report, the Statutory Financial Statements and theConsolidated Financial Statements for Fiscal Year 2020

The Board of Directors proposes that the annual report, the statutory financial statements and the consolidated financial statements of ObsEva SA for fiscal year 2020 be approved.

2Discharge of Liability for the Members of the Board of Directors and of the Executive Committee.

The Board of Directors proposes that shareholders release the members of the Board of Directors and of the Executive Committee from liability for their activities during fiscal year 2020.

3Appropriation of Financial Results.

The Board of Directors proposes that the loss of USD 75,216,317 for the financial year 2020 be appropriated as follows:

Financial Year 2020
Accumulated losses brought forward from previous yearUSD 253,235,253
Net loss for the year 2020USD 75,216,317
Accumulated losses to be carried forwardUSD 328,451,570


4Elections to the Board of Directors and Election of the Chairman of the Board of Directors

The Board of Directors proposes the re-election of the following nominees for a term of one year expiring at the closing of the 2022 Annual General Meeting:

4.1        Re-election of Franciscus Verwiel as member and Chairman of the Board of Directors
4.2        Re-election of Annette Clancy as member of the Board of Directors
4.3        Re-election of Barbara Duncan as member of the Board of Directors
4.4        Re-election of Ernest Loumaye as member of the Board of Directors
4.5        Re-election of Edward Mathers as member of the Board of Directors
4.6        Re-election of Jacky Vonderscher as member of the Board of Directors

Jim Irvin Healy and Rafaele Elisabete Tordjman are not standing for re-election.

The Board of Directors further proposes the election of the following nominees for a term of one year expiring at the closing of the 2022 Annual General Meeting:

4.7        Election of Catarina Edfjäll as member of the Board of Directors

Catarina Edfjäll is a Global Regulatory Affairs Expert with more than 25 years of experience in the biotech and pharma sector, now working as an independent consultant and mentor. She has profound drug development experience across the entire product lifecycle, from development to launch, and across many therapeutic areas, including rare diseases. She was responsible for the successful regulatory approval of 20 innovative medicinal products and new indications in more than 50 countries. In her most recent senior management role, Catarina was the global head of regulatory affairs at CSL Behring. Prior to that, she held leadership positions in regulatory affairs at companies formerly known as Actelion, Celgene and Shire, and, started her career at F. Hoffmann-La Roche.

Catarina is a Board Member at the Cancer Drug Development Forum (CDDF) and at the International Collaboration on Rare Diseases & Orphan Drugs (ICORD), both non-profit organisations. She has been actively involved in several multi-stakeholder organisations, including the European Medicines Agency´s Committee for Orphan Medicinal Products´ Working Group with Interested Parties.

Catarina holds a Master in biotechnology engineering from the Ecole Supérieure de Biotechnologie in Strasburg, a Ph.D. in biochemistry from the University in Basel and a Corporate Governance Certification from the Swiss Board School and the University of St Gallen.

The mandate of Catarina Edfjäll as member of the Board of Directors would only be effective as of June 30, 2021.

4.8        Election of Brian O’Callaghan as member of the Board of Directors

Brian O’Callaghan is a Life Science Executive with extensive experience within the biotech, big pharma and CRO sectors. He also has extensive global experience, having lived and worked in 5 different countries, as well as both sides of the US. He joined ObsEva in November 2020, as Chief Executive Officer to lead the Company through its future development, regulatory filings and product launches.

Prior to joining ObsEva, Brian has held CEO positions at Petra Pharma, Acucela, Sangart and BioPartners, as well as having held senior management positions at Pfizer, Merck Serono, Novartis, Covance and NPS Pharmaceuticals.

Brian has experience running both public and private companies, M&A’s, IPO’s, fundraising, divestments, spin-outs and strategic alliances. His operational experience is also wide ranging, having managed multiple businesses and programs, across many therapeutic areas, from concept through to commercialization. He also has extensive Board experience, having served on numerous biotech and 501c3 Boards.

5Elections to the Compensation Committee

The Board of Directors proposes the re-election of the following nominees for a term of one year expiring at the closing of the 2022 Annual General Meeting:

5.1        Re-election of Annette Clancy as member of the Compensation Committee
5.2        Re-election of Edward Mathers as member of the Compensation Committee

Jim Irvin Healy and Rafaele Elisabete Tordjman are not standing for re-election.

The Board of Directors further proposes the election of the following nominee for a term of one year expiring at the closing of the 2022 Annual General Meeting:

5.3        Election of Catarina Edfjäll as member of the Compensation Committee

The mandate of Catarina Edfjäll as member of the Compensation Committee would only be effective as of September 30, 2021.

6Re-election of PricewaterhouseCoopers SA as ObsEva SA's Auditors and Independent Registered Public Accounting Firm

The Board of Directors proposes the re-election of PricewaterhouseCoopers SA as ObsEva SA's auditors and independent public accounting firm for the fiscal year 2021.

7Re-election of Perréard de Boccard SA as Independent Representative

The Board of Directors proposes the re-election of Perréard de Boccard SA, Rue de la Coulouvrenière 29, 1204 Genève, as Independent Representative of shareholders for a one-year term expiring at the closing of the 2022 Annual General Meeting.

8Compensation of the Board of Directors and the Executive Committee

8.1        Approval of the Compensation of the Board of Directors

The Board of Directors proposes that the shareholders approve a maximum aggregate amount of compensation of USD 2,500,000 for the members of the Board of Directors for the period from the 2021 Annual General Meeting to the 2022 Annual General Meeting.

8.2        Approval of the Compensation of the Executive Committee for the Fiscal Year 2022

The Board of Directors proposes that the shareholders approve a maximum aggregate amount of compensation of USD 13,000,000 for the members of the Executive Committee for the fiscal year 2022, subject to potential adjustment due to the fluctuation of the applicable exchange rate.

9Increase of ObsEva SA's Authorized Share Capital

The Board of Directors proposes to increase to 40,610,232, the number of new ordinary shares that can be issued under the authorized share capital of ObsEva SA. For this purpose, the Board of Directors proposes to create a new authorized share capital, so that the Board of Directors be authorized to increase ObsEva SA's share capital until 28 May 2023, by the issuance of up to 40,610,232 new shares.

10Increase of ObsEva SA's Conditional Share Capital for Financing Purposes

The Board of Directors proposes to increase by 13,325,051, corresponding to an increase from 13,527,073 to 26,852,124, the number of new ordinary shares that can be issued upon exercise of option and conversion rights that may be granted in connection with bonds, similar debt instruments, loans or other financial market instruments or contractual obligations of the Company or one of its subsidiaries, and/or upon exercise of option rights issued by the Company or one of its subsidiaries.

11Increase of ObsEva SA's Conditional Share Capital for Equity Plans

The Board of Directors proposes to increase by 4,753,671, corresponding to an increase from 9,004,437 to 13,758,108, the number of new ordinary shares that can be issued upon exercise of options or pre-emptive rights thereof, which have been issued or granted to employees, members of the Board of Directors or consultants of ObsEva SA or of one of its subsidiaries under the terms of one or more equity incentive plans or regulations adopted by the Board of Directors.

12Approval of change to ObsEva SA’s Equity Incentive Plan

Subject to approval of Proposal 11, the Board of Directors proposes to the shareholders to increase by 4,753,671, from 9,126,742 to 13,880,413, the number of new ordinary shares that can be issued under the Plan, and to amend Article 3 (a) of the Plan accordingly.

The full invitation to the AGM 2021 may be found in the general meetings section of the Company’s website, [here]. To access the invitation to the AGM 2021 directly, please click [here].

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

For further information, please contact:

CEO Office Contact:

Shauna Dillon

Shauna.dillon@obseva.ch

+41 22 552 1550

Investor Contact:

Joyce Allaire

jallaire@lifesciadvisors.com

+1 (617)-435-6602

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Novo Nordisk A/S – Share repurchase programme7.5.2021 21:31:30 CEST | Press release

Bagsværd, Denmark, 7May2021 — As part of the up to DKK 18 billion 2021 share repurchase programme, Novo Nordisk A/S has now initiated a new share repurchase programme for an amount of up to DKK 3.3 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”). For that purpose, Novo Nordisk A/S has appointed Skandinaviska Enskilda Banken, Danmark, filial af Skandinaviska Enskilda Banken AB, as lead manager to execute the programme independently and without influence from Novo Nordisk A/S. The purpose of the programme is to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes. Under the agreement, Skandinaviska Enskilda Banken, Danmark, filial af Skandinaviska Enskilda Banken AB, will repurchase B shares on behalf of Novo Nordisk A/S during the trading period starting 10 May 20

Novo Nordisk A/S purchases B shares worth DKK 2,586 million from Novo Holdings A/S under the 2021 share repurchase programme7.5.2021 21:24:00 CEST | Press release

Bagsværd, Denmark, 7 May2021 — Novo Nordisk A/S has today entered into an agreement to purchase 5,610,000 B shares of DKK 0.20 to a value of DKK 2,586 million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S’ 2021 share repurchase programme of up to a total of DKK 18 billion to be executed during a 12-month period beginning 3 February 2021. The transaction price is DKK 461.04 per share and has been calculated as the three-day volume weighted average market price from 5 May 2021 to 7 May 2021 in the open window following the announcement of Novo Nordisk A/S’ quarterly financial results. Prior to the sale of B shares, Novo Holdings A/S’ ownership of Novo Nordisk A/S was 28.5% of the share capital and 76.9% of the votes. Following the transaction, Novo Holdings A/S owns 537,436,000 A shares of DKK 0.20 and 116,129,000 B shares of DKK 0.20, corresponding to 28.3% of the capital and 76.8% of the votes in Novo Nordisk A/S. The transaction is in line with the announcement

RomReal: Mandatory notification of insider trade - Chairman and CEO of RomReal Kjetil Gronskag7.5.2021 19:34:48 CEST | Press release

Kjetil Gronskag, Chairman and CEO of RomReal Ltd has today 07 May 2021, purchased 2000 shares of RomReal at NOK 1.74 per share in RomReal Ltd. Following this trade, Kjetil Gronskag controls privately and through holding companies 4,546,127 shares in RomReal Ltd. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

PRFOODS NOTICE OF NOTEHOLDERS’ MEETING7.5.2021 16:58:01 CEST | Press release

AS PRFoods (registry code 11560713, registered address at Pärnu mnt 141, 11314 Tallinn, Estonia; “PRFoods”) hereby notifies persons holding the notes (the “Noteholders”) of the Issuer, due on 22 January 2025 and bearing ISIN code EE3300001577 (the “Notes”), issued under the Terms and Conditions of Secured Note Issue of AS PRFoods dated 14 January 2020 (which have been amended on 25 February 2020; the “Terms”), of convening a meeting of Noteholders (the “Meeting”). The Meeting will be held on 24 May 2021 at 12:00 (EET) at Peetri 12 (Kai Kunstikeskus), 10415 Tallinn, Estonia. Registration for the Meeting will be open at the venue of the Meeting from 11:00 to 11:45 (EET). The management of PRFoods requests all Noteholders to consider that due to COVID-19 caused by the coronavirus, it is advised to minimise the extent of physical gatherings and the participation therein. For this purpose, the management of PRFoods advises to consider authorising representatives of the collateral agent to p

AS PRFoods is Planning an Issue of Subordinated Convertible Notes and Tap-Issue of Secured Notes7.5.2021 16:44:03 CEST | Press release

THIS NOTICE IS NOT INTENDED FOR PUBLICATION, ALLOCATION OR TRANSMISSION, IN PART OR WHOLLY, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR ELSEWHERE THE DISCLOSURE OR TRANSMISSION OF THIS INFORMATION IS NOT ALLOWED. AS PRFoods (registry code 11560713, “PRFoods”) announces that due to the continuing pandemic caused by COVID-19 and the extraordinary effects the pandemic and the measures implemented to combat the pandemic have had on the economic environment, including on the economic operations of PRFoods during the pending 2020/2021 financial year (i.e. the financial year 01.07.2020 – 30.06.2021), PRFoods deems necessary to reinforce its capital structure for the purposes of ensuring a smoother and faster recovery from the negative impacts caused by COVID-19 in the upcoming 2021/2022 financial year (i.e. financial year 01.07.2021 – 30.06.2022). In connection with the above, PRFoods hereby informs that, for the

CONDITIONS FOR PURCHASES OF CORPORATE BONDS7.5.2021 16:20:00 CEST | Press release

Bid procedure, 2021-05-12BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: ELLEVIO AB: XS1562583937, 2024-02-28 HUSQVARNA AB: SE0013359486, 2024-12-04 HUSQVARNA AB: SE0010869677, 2023-02-14 LUNDBERGFORETAGEN AB: SE0012676609, 2025-11-13 LUNDBERGFORETAGEN AB: SE0009241524, 2023-10-24 WILLHEM AB: SE0012193985, 2025-02-22 WILLHEM AB: SE0013882966, 2024-04-08 CASTELLUM AB: SE0011062827, 2023-05-17 CASTELLUM AB: SE0012675916, 2025-11-27 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2021-04-12Bid date2021-05-12Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)XS1562583937: 30 mln SEK +/-30 mln SEK SE0013359486: 30 mln SEK +/-30 mln SEK SE0010869677: 30 mln SEK +/-30 mln SEK SE0012676609: 30 mln SEK +/-30 ml

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS7.5.2021 16:20:00 CEST | Press release

Bid procedure, 2021-05-14BondsSWEDEN I/L BOND: 3113. SE0009548704. 2027-12-01 SWEDEN I/L BOND: 3111, SE0007045745, 2032-06-01 Bid date2021-05-14Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)3113: 500 mln SEK +/-250 mln SEK 3111: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)3113: 500 mln SEK per bid 3111: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-05-18Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-05-07 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be